EdiGene, a clinical-stage biotech, aims to develop gene editing treatments for genetic diseases, including beta-thalassemia, lymphoma, and neuromuscular diseases. Their technology utilizes bioinformatics, high-throughput genome-editing screening, CRISPR/Cas9 and Leveraging endogenous ADAR for programmable editing of RNA (LEAPER) LEAPER is an RNA editing method developed by Wensheng Wei, the scientific founder of EdiGene. The company was founded in 2015 with headquarters in Beijing and a new R&D Center in Waltham, Massachusetts.

EdiGene (2)

Founded: 2015
Location: Beijing, China
Employee range: 50 - 200
Clinical stage: Clin1
Therapy area: Beta thalassemia
Drug types: HEM, GEN, ONC, OPH, NEU
Lead product: ET-01
Funding: $62M B+ Apr 2021; $67M B Oct 2020; $11M Sep 2019; $10M A Feb 2019

Drug notes:

About:

Jobs: